Cite
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
MLA
Melissa Bersanelli, et al. “PD-L1 SNPs as Biomarkers to Define Benefit in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors.” Tumori, vol. 108, no. 1, May 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9625c96252d00a46b818441e7c6dd778&authtype=sso&custid=ns315887.
APA
Melissa Bersanelli, Francesco Bonatti, Sebastiano Buti, Agnese Cosenza, Paola Bordi, Roberta Minari, Marcello Tiseo, Francesco Facchinetti, Gloria Cinquegrani, Andrea Ardizzoni, Elena Rapacchi, Leonarda Ferri, Alessandro Leonetti, Federico Quaini, Alessandra Dodi, Giulia Mazzaschi, Anna Squadrilli, & Francesco Gelsomino. (2021). PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori, 108(1).
Chicago
Melissa Bersanelli, Francesco Bonatti, Sebastiano Buti, Agnese Cosenza, Paola Bordi, Roberta Minari, Marcello Tiseo, et al. 2021. “PD-L1 SNPs as Biomarkers to Define Benefit in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors.” Tumori 108 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9625c96252d00a46b818441e7c6dd778&authtype=sso&custid=ns315887.